IL17A and urinary bladder carcinoma: The above analyses revealed that the regulation of gene expression in bladder cancer cells by Disitamab Vedotin mainly focused on the IL-17 signaling pathway, TNF signaling pathway, NF-κB signaling pathway, and cytokine–cytokine receptor interaction pathway.